- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02460289
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
July 14, 2023 updated by: Galderma R&D
Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 5% Foam and Botanical Hair Solution Regimen in Men With Thinning Hair and Male Pattern of Hair Loss/Androgenic Alopecia (Norwood III & IV)
The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III & IV).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Richardson, Texas, United States, 75081
- Stephens & Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Male patients age 18 to 60 years at the time of enrollment.
- Men who have self-perceived thinning hair.
- Men who have presentation of male pattern hair loss/androgenic alopecia (Norwood III & IV).
Key Exclusion Criteria:
- History of allergic reactions or severe intolerance to minoxidil and Botanical Hair Solution product ingredients.
- Plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study.
3 Subjects taking or planning to take topical or systemic prescription or OTC medications for treating hair loss and/or hair volume.
4. Any significant history of concurrent medical disease, which in the judgment of the Investigator, would make the subject inappropriate for entry to this study including history of skin disease that may confound study results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12
Time Frame: At Week 12
|
The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale.
Investigator global photograph rating were assessed using 7-point Likert scale.
Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.
|
At Week 12
|
Change From Baseline in Participant Rating at Week 12
Time Frame: At Week 12
|
Participants rated the parameters like appearance of hair, growth of hair, satisfaction with hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale.
Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.
|
At Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in Shed Hair Count
Time Frame: At Week 12
|
Participants collected their hair full day, including after combing and hair-washing.
Participants turned in these hair collections at each visit.
The results were averaged weekly.
Mean change from baseline in hair wash/shed hair count was reported at Week 12.
|
At Week 12
|
Number of Participant in Each Response Category Based on Subject Satisfaction Questionnaire
Time Frame: At Week 4,6 and 12
|
Participant's satisfaction questionnaire was used to specifically collect the participants' feedback on the treatment regimen, the level of satisfaction and future usage.
Participants were asked to complete a cosmetic acceptability questionnaire.
This 10 item questionnaire had a 5-point Likert Response Scale (1=Strongly Agree; 5=Strongly Disagree).
|
At Week 4,6 and 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs)
Time Frame: From start of study up to Week 12
|
AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related.
An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality.
An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose.
Thus, any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE.
Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE.
Any worsening in scalp dryness or itch score from baseline was also reported as an AE.
The Investigator or designee had the final authorization to determine if a reaction was considered an AE.
|
From start of study up to Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Warren Winkelman, MD, PhD, MBA, Galderma R&D
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 19, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
May 29, 2015
First Submitted That Met QC Criteria
May 29, 2015
First Posted (Estimated)
June 2, 2015
Study Record Updates
Last Update Posted (Actual)
August 1, 2023
Last Update Submitted That Met QC Criteria
July 14, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLI.04.SPR.US 10329
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Pattern of Hair Loss, Androgenic Alopecia
-
Galderma R&DCompletedFemale Pattern Hair Loss, Androgenic AlopeciaUnited States
-
Kaohsiung Medical University Chung-Ho Memorial...CompletedFemale Pattern Alopecia | Androgenic Alopecia | Male Pattern Baldness | Hair Loss/BaldnessTaiwan
-
University of MinnesotaWithdrawnAndrogenetic Alopecia | Male Pattern Baldness | Male Pattern Hair LossUnited States
-
StimuSILAnkara City Hospital Bilkent; Istanbul University - Cerrahpasa (IUC)RecruitingAndrogenetic Alopecia | Hair Loss | Male Pattern Baldness | Hair Loss/Baldness | Pattern BaldnessTurkey
-
Duke UniversityCompletedAndrogenetic Alopecia | Male Pattern Hair Loss
-
HistogenCompleted
-
Lexington International, LLCCompletedAndrogenetic Alopecia | Hair Loss | Male Pattern BaldnessUnited States
-
Suzhou Kintor Pharmaceutical Inc,CompletedTo Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic AlopeciaAlopecia | Male Pattern Hair LossUnited States
-
Lexington International, LLCCompletedAndrogenetic Alopecia | Hair Loss | Male Pattern BaldnessUnited States
-
Arbor Life LabsCompletedAndrogenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning HairUnited States
Clinical Trials on Treatment: Minoxidil 5% / Botanical Hair Solution for Men
-
Galderma R&DCompletedFemale Pattern Hair Loss, Androgenic AlopeciaUnited States
-
Dermaliq Therapeutics, Inc.CompletedAndrogenetic AlopeciaAustralia
-
Roswell Park Cancer InstituteCelldex TherapeuticsCompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated CellsUnited States
-
Tampere UniversityFinnish Cultural Foundation; Sigrid Jusélius Foundation; Päivikki and Sakari... and other collaboratorsRecruitingRenal Insufficiency | Aortic Stenosis | Primary Hypertension | Secondary HypertensionFinland